神州细胞：预计2025年亏损5.2亿元至5.8亿元，多个在研项目报告期内进入临床试验阶段

Core Viewpoint - The company expects a net loss attributable to shareholders of 520 million to 580 million yuan for 2025, with a non-recurring net loss projected at 503 million to 563 million yuan, alongside a research and development investment of 830 million to 870 million yuan for the same year [1] Group 1 - The company has experienced a significant decline in sales revenue due to ongoing industry policy changes and multiple price reductions of its core product, Anjia [1] - The overall operating revenue of the company is expected to decrease compared to the same period last year [1] - The company has increased its commercialization investments, including academic promotion and the establishment of a sales team, leading to a noticeable short-term increase in sales expenses [1] Group 2 - The company continues to maintain high levels of research and development investment, which impacts its current profitability [1]